• Savara Inc. announced that its Phase 3 IMPALA-2 data for molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP) will be featured in one oral and two poster presentations at the ERS Congress in Barcelona in early September 2026, highlighting long-term efficacy, safety, and biomarker findings.
• The company emphasized that these results point to sustained improvements in lung function, exercise capacity, and quality of life in aPAP patients, a rare group that currently lacks any approved pharmacologic treatments.
• Next, we will examine how molgramostim’s Phase 3 data and its potential as a long-term aPAP therapy shape Savara’s investment narrative.

Find 49 companies with promising cash flow potential yet trading below their fair value.

What Is Savara's Investment Narrative?

To own Savara, you really have to believe that molgramostim (MOLBREEVI) can transition from a promising Phase 3 asset into an approved and commercialized therapy for aPAP, effectively carrying the whole company. The latest ERS Congress acceptance reinforces the scientific and clinical story behind molgramostim and modestly strengthens the near term catalyst stack by adding more long term efficacy and biomarker data into the public domain ahead of the November 2026 PDUFA date. That said, the core short term swing factor is still the extended FDA review, not the congress spotlight, while the biggest risks remain binary regulatory outcomes, zero current revenue, widening net losses of around US$77.51 million in the first half of 2026, and potential further dilution given the recent increase in authorized shares.

However, one key financing risk here is something investors should not overlook. The valuation report we've compiled suggests that Savara's current price could be inflated.

Exploring Other Perspectives

Investors in the Simply Wall St Community have shared 1 fair value estimate, all clustering around US$10.94 per share, which hints at limited dispersion in their expectations. Set that against the company’s single product focus and binary FDA decision in late 2026, and you can see why it pays to compare several viewpoints before forming your own view on Savara’s prospects.

Explore another fair value estimate on Savara - why the stock might be worth as much as 97% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Savara research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Savara research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Savara's overall financial health at a glance.

Ready For A Different Approach?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.